IPO
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange
Telix Pharmaceuticals Raises $400M in Bond Sale Amid IPO Uncertainty
Telix Pharmaceuticals, Bond Sale, IPO, Radiopharma, Funding
Artiva Biotherapeutics Seeks $116M in Second IPO Attempt for Cell Therapy Development
Artiva Biotherapeutics, IPO, cell therapy, AlloNK, systemic lupus erythematosus, autoimmune diseases
Artiva Pursues IPO to Fund NK Cell Therapy After Losing Merck Partnership
Artiva, Merck, IPO, NK Cell Therapy, Biotech, Partnership, Funding
Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research
Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology
Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor
Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology
Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings
Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings
Rapport, a J&J Neuroscience Spinout, Prepares for Summer IPO as the First Biotech of the Season
Rapport, IPO, J&J, neuroscience, biotech, summer plans, Third Rock.
Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering
Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health